EYE C BETTER

Eye C Better finalizes agreement to develop world’s first non-contact device

Eye C Better finalizes agreement to develop world’s first non-contact device

Eye C Better Corp. Finalizes Agreement to Develop the World’s first Non-Contact Device for Managing Glaucoma at Home

Indio, California, March 10, 2022 Eye C Better Crop.  is proud to announce the signing of an exclusive and worldwide License and Research Agreement with BIRAD Research and Development Company Ltd. and the Universitat de Valencia for Patent Rights to technology using optical sensors, sound waves, and speckle patterns that will measure intra-ocular pressure which is the most important factor related to glaucoma. The Agreement includes 24 granted patents and two pending patents.

There are currently over 100 million people affected by glaucoma which is  the leading cause of irreversible blindness worldwide.  Glaucoma is generally caused by the accumulation of excess intraocular fluid which leads to high eye pressure.  In cases of glaucoma, the intraocular pressure is high enough to cause damage to the optic nerve either by mechanical compression of the nerve itself or by a restriction of blood flow to the area. Damage to the optic nerve will materially degrade the visual system and lead to sight loss and ultimately blindness. 

Accurate and precise intra-ocular pressure (IOP) measurements are critical to the evaluation, diagnosis, treatment, and management of a patient’s glaucoma. Clinical treatment and management decisions rely on these intra-ocular measurements. The current accuracy and number of measurements is considered sub-optimal at best.  The intra-ocular pressure measurements are critical for a clinician to be able to properly manage the pressure and slow the progressive of optic nerve damage and its subsequent associated visual field loss. There is a need for a device and system that allows for significantly more intra-ocular pressure measurements and realistically this can only be accomplished with a home-device. Eye C Better has developed a breakthrough medical device with technology to transform the treatment of glaucoma. Patients with glaucoma continue to need care when they leave the doctor’s office and Eye C Better provides individuals with the tools to manage, monitor, and maintain their glaucoma while preventing the loss of vision from progressing.  

Chad Wasilenkoff, CEO and co-founder says, “We are excited to have secured this breakthrough technology which will form the core of our Eye C Better solution to provide at home intra-ocular pressure measurements for those suffering with the blinding disease of glaucoma. Our company was built knowing the problem and what was needed and then we spent years looking at and evaluating various solutions to best be able to solve this problem.  After securing numerous early-stage technologies we were finally able to reach an agreement with BIRAD Research and Development Company Ltd. and the Universitat de Valencia to secure this world-leading technology to measure infra-ocular pressure.  Our Eye C Better team of professionals are all driving towards the same goal to help prevent vision loss caused by glaucoma.  We are excited to bring this diagnosis and treatment of glaucoma into the 21st century.  Our offerings will allow for accurate measurement on a more regular and convenient basis which will result in more eye pressure measurements, resulting in overall better treatment.   With a clear path towards FDA approval and a reimbursement structure already in place, a significant amount of obstacles has already been removed.  We are a motivated team that is ready to bring this technology to the world.”

ABOUT EYE C BETTER CORP.

Eye C Better (ECB) is a Medical Technology as a Service (MedTaaS) company that combines a breakthrough medical device with digital technology to transform glaucoma healthcare. People with glaucoma continue to need care when they leave the doctor’s office and Eye C Better provides individuals with the tools to manage, monitor and maintain their disease.  Glaucoma is caused by elevated eye pressure which damages the optic nerve.  Keeping that pressure within an acceptable range is critical to stopping this blinding disease. Current glaucoma treatment plans typically have a patient only measuring their pressure a few times a year, their pressure can fluctuate up to 10mmHg per day and the current device can have accuracy challenges resulting in up to a 10mmHg misreading or more.  Yet a doctor will change their treatment based on a 1 mmHg change in pressure.  Our device will be able to gather numerous pressure measurements throughout a typical day allowing a doctor to better understand a patient’s eye pressure, effectiveness of eye-drops, and be able to make better recommendations to measure, monitor, and maintain healthy eye pressures.  More eye pressure measurements will lead to better patient outcomes and help those people with glaucoma enjoy a lifetime of vision. 

Eye C Better Corp. is currently raising a $20 million Series A financing to advance our technology and overall solution which is needed by the glaucoma community.

Eye C Better envisions all people enjoy a lifetime of healthy vision. At Eye C Better, it is our highest priority to establish awareness to the importance of early and regular Glaucoma screening to prevent vision loss and blindness, and to make available to all affordable medical testing equipment and medication to fight the disease.

 

To learn more about Eye C Better Corp., visit www.eyecbetter.com

Main Phone: 669-244-5849

www.linkedin.com/company/eyecbetter/about/